Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

1234 5678

PO Box 3787

South Brisbane QLD 4101

ERX-315-101

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Open for recruitment

Trial summary

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

The goal of this open-label, dose escalation and cohort expansion Phase 1 clinical trial is to determine the safety, tolerability and pharmacokinetics of ERX-315 in patients with advanced solid tumors, who have progressed on prior approved systemic therapies. Participants will receive ERX-315 as an intravenous (IV) injection twice a week, over 21-day cycles.

Trial details

Short title

ERX-315-101

Diagnosis

Advanced solid tumours

Type of treatment

Medical Oncology

Phase

I

Locations

Investigators

Principal Investigators

Who can participate

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.